e-learning
resources
Munich 2006
Tuesday 05.09.2006
Pathophysiology and treatment of infections in COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effectiveness of 23-valent pneumococcal polysaccharide vaccine in preventing lower respiratory tract infections complicating chronic respiratory failure
M. Sumitani, Y. Tochino, T. Kamimori, H. Fujiwara, T. Fujikawa (Osaka City, Japan)
Source:
Annual Congress 2006 - Pathophysiology and treatment of infections in COPD
Session:
Pathophysiology and treatment of infections in COPD
Session type:
Electronic Poster Discussion
Number:
3384
Disease area:
Airway diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Sumitani, Y. Tochino, T. Kamimori, H. Fujiwara, T. Fujikawa (Osaka City, Japan). Effectiveness of 23-valent pneumococcal polysaccharide vaccine in preventing lower respiratory tract infections complicating chronic respiratory failure. Eur Respir J 2006; 28: Suppl. 50, 3384
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
From pulmonary gas exchange to the interpretation of arterial blood gases
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Impaired response to 13-valent pneumococcal conjugate vaccine (PCV13) in children with recurrent respiratory infections and chronic cough.
Source: Virtual Congress 2021 – Paediatric respiratory infections: chronic infection, vaccination and lung function
Year: 2021
Effects of pneumococcal vaccine in patients with chronic respiratory disease
Source: Annual Congress 2007 - Different aspects of COPD exacerbations
Year: 2007
Effects of pneumococcal vaccine in patients with chronic respiratory disease
Source: Eur Respir Rev 2008; 17: 43-45
Year: 2008
No preventive effects of 23-valent pneumococcal polysaccharide vaccine in patients with chronic renal failure
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly
Source: Eur Respir J 2010; 36: 608-614
Year: 2010
Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes
Source: Eur Respir J 2014; 43: 545-553
Year: 2013
Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases
Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit
Year: 2018
Should pneumococcal vaccines be used to prevent LRTI?
Source: Annual Congress 2009 - PG1 EU GRACE Network Full-day Course: vaccination and preventive measures for LRTIs in the community: what’s new?
Year: 2009
Investigation of factors associated with result of pneumococcal urinary antigen in the microbiological investigation of pneumococcal lower respiratory infections
Source: International Congress 2017 – CAP: severity scores, risk groups and biomarkers
Year: 2017
Simultaneous use of probiotics and vaccines for prevention of pneumonia and respiratory infections in servicemen
Source: Eur Respir J 2006; 28: Suppl. 50, 154s
Year: 2006
Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine
Source: Eur Respir J 2013; 42: 1595-1603
Year: 2013
The remaining challenges of pneumococcal disease in adults
Source: Eur Respir Rev 2012; 21: 57-65
Year: 2012
Effectiveness of polysaccharide pneumococcal vaccination among subjects with chronic obstructive pulmonary disease
Source: Eur Respir J 2006; 28: Suppl. 50, 442s
Year: 2006
Results of vaccination against pneumococcal infection in patients with chronic heart failure
Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections
Year: 2020
Analysis of efficiency of joint or consistent vaccination with pneumococcal and influenzal vaccines in patients with chronic obstructive pulmonary disease
Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies
Year: 2019
Impact of pneumococcal vaccination in children in the distribution of serotypes in bacteriemic pneumococcal pneumonia in adults
Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept